Who can use BRAFTOVI(Encorafenib)?
Who can use BRAFTOVI(Encorafenib)?
Melanoma
Binimetinib combined with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic BRAFV600E/K mutation-positive melanoma.
Colorectal Cancer (CRC)
Encorafenib in combination with cetuximab and the mFOLFOX6 regimen (fluorouracil, leucovorin, oxaliplatin) is used as first-line therapy (accelerated approval) for adult patients with BRAFV600E mutation-positive metastatic colorectal cancer.
Encorafenib combined with cetuximab is indicated for adult patients with BRAFV600E mutation-positive metastatic colorectal cancer who have failed prior therapy.
Non-Small Cell Lung Cancer (NSCLC)
Encorafenib combined with binimetinib is used for the treatment of adult patients with BRAFV600E mutation-positive metastatic non-small cell lung cancer.
